SCHEMBL17424332

SCHEMBL17424332

Cc1cc(Nc2ccccc2C(=O)O)ccc1I

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAS2R14 Q9NYV8 8/20 0.61
▸ FABP4 P15090 2/20 0.55
▸ AKR1C3 P42330 6/20 0.54
▸ AKR1C2 P52895 5/20 0.54
▸ PTGS1 P23219 4/20 0.54
▸ PTGS2 P35354 4/20 0.54
▸ MEN1 O00255 4/20 0.54
▸ KMT2A Q03164 4/20 0.54
▸ AKR1B10 O60218 3/20 0.54
▸ AKR1C1 Q04828 3/20 0.54
▸ CYP1A2 P05177 3/20 0.54
▸ ABCB11 O95342 2/20 0.54
▸ CHRM1 P11229 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ CYP3A4 P08684 2/20 0.54
▸ CYP2C9 P11712 2/20 0.54
▸ AKR1B1 P15121 2/20 0.54
▸ HIF1A Q16665 2/20 0.54
▸ TRPA1 O75762 1/20 0.54
▸ DHFR P00374 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14580629 0.86 TAS2R14 (0.70) TAS2R14FABP4AKR1C3AKR1C2PTGS1
SCHEMBL2625434 0.82 TAS2R14 (0.65) TAS2R14FABP4AKR1C3AKR1C2PTGS1
SCHEMBL1649780 0.82 TTR (0.62) TAS2R14FABP4AKR1C3AKR1C2PTGS1
SCHEMBL11611911 0.79 TTR (0.67) TAS2R14FABP4AKR1C3AKR1C2PTGS1
SCHEMBL18109767 0.79 FABP4 (0.85) TAS2R14FABP4AKR1C3AKR1C2PTGS1
SCHEMBL4249837 0.78 FABP4 (0.71) TAS2R14FABP4AKR1C3AKR1C2PTGS1
SCHEMBL5680799 0.78 FABP4 (0.71) TAS2R14FABP4AKR1C3AKR1C2PTGS1
SCHEMBL28133218 0.77 FABP4 (0.75) TAS2R14FABP4AKR1C3AKR1C2PTGS1
SCHEMBL10144302 0.77 AKR1C3 (0.68) TAS2R14FABP4AKR1C3AKR1C2PTGS1
SCHEMBL29391834 0.77 AKR1C3 (0.68) TAS2R14FABP4AKR1C3AKR1C2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9233107-B2 Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (PML) BIOGEN MA INC. (US) 2016-01-12 — — US disclosed
Send feedback